Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patriarca

Showing results (991-1000 of 1,012) with videos related to

Pageof 102
Sort By:
American Journal of Hematology|December 10, 2019
Second cancers in MPN: Survival analysis from an international studyMonia Marchetti, Arianna Ghirardi, Arianna Masciulli, et al.
Blood Advances|May 7, 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDSAmy E DeZern, Sylvain Thepot, Stéphane De Botton, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2022
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancerDavid J Pinato, Daniela Ferrante, Juan Aguilar-Company, et al.
Haematologica|August 3, 2019
Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemiaFary Diop, Riccardo Moia, Chiara Favini, et al.
Leukemia|January 8, 2021
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinibTiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, et al.
Blood Cancer Journal|February 10, 2021
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19Tiziano Barbui, Valerio De Stefano, Alberto Alvarez-Larran, et al.
International Journal of Cancer|January 6, 2010
Cancer incidence in people with AIDS in ItalyJerry Polesel, Silvia Franceschi, Barbara Suligoi, et al.
Hematological Oncology|May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trialsAntonella Bruzzese, Daniele Derudas, Monica Galli, et al.
The Lancet. Haematology|October 14, 2019
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trialDietrich Wilhelm Beelen, Rudolf Trenschel, Matthias Stelljes, et al.
Journal for Immunotherapy of Cancer|March 23, 2021
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory ScoreGino M Dettorre, Saoirse Dolly, Angela Loizidou, et al.
Pageof 102

Showing results (991-1000 of 1,012) with videos related to

Sort By:
Pageof 102
American Journal of Hematology|December 10, 2019
Second cancers in MPN: Survival analysis from an international studyMonia Marchetti, Arianna Ghirardi, Arianna Masciulli, et al.
Blood Advances|May 7, 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDSAmy E DeZern, Sylvain Thepot, Stéphane De Botton, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2022
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancerDavid J Pinato, Daniela Ferrante, Juan Aguilar-Company, et al.
Haematologica|August 3, 2019
Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemiaFary Diop, Riccardo Moia, Chiara Favini, et al.
Leukemia|January 8, 2021
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinibTiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, et al.
Blood Cancer Journal|February 10, 2021
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19Tiziano Barbui, Valerio De Stefano, Alberto Alvarez-Larran, et al.
International Journal of Cancer|January 6, 2010
Cancer incidence in people with AIDS in ItalyJerry Polesel, Silvia Franceschi, Barbara Suligoi, et al.
Hematological Oncology|May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trialsAntonella Bruzzese, Daniele Derudas, Monica Galli, et al.
The Lancet. Haematology|October 14, 2019
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trialDietrich Wilhelm Beelen, Rudolf Trenschel, Matthias Stelljes, et al.
Journal for Immunotherapy of Cancer|March 23, 2021
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory ScoreGino M Dettorre, Saoirse Dolly, Angela Loizidou, et al.
Pageof 102